keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Neuropeptide Y (human) TFA, a compound implicated in Alzheimer's disease (AD), exhibits protective effects against β-Amyloid toxicity in rat cortical neurons.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 148.00 | |
5 mg | Inquiry | $ 598.00 |
Description | Neuropeptide Y (human) TFA, a compound implicated in Alzheimer's disease (AD), exhibits protective effects against β-Amyloid toxicity in rat cortical neurons. |
In vitro | Neuropeptide Y (human) has been shown to shield cortical neurons from the toxicity of Aβ25-35. At concentrations of 2 μM, it counteracts the harmful effects of Aβ25-35 at both 24 and 48 hours. This protective impact on neuronal survival is consistent across neurons pre-exposed to 1 μM and 0.5 μM Neuropeptide Y (human) treatments. Furthermore, pretreatment with Neuropeptide Y (29-64), amide, human (TFA), enhances NGF synthesis and release while reducing NGF mRNA levels in cortical neurons challenged with Aβ35-25[1]. |
Molecular Weight | N/A |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Neuropeptide Y (human) (TFA) Neuropeptide Y inhibitor inhibit